For the Inventor, By the Inventor

Enter assignee name

Aachen, Germany

Grunenthal Gmbh

USPTO Granted Patents = 107

CIPO Patents = 9

EPO Patents = 233

Forward Citations = 983

Loading Chart...

Loading Chart...

187 inventors (with patents filed for the assignee):

Johannes Bartholomäus (18 out of 28 patents)

Florian Jakob (15 out of 24 patents)

Heinrich Kugelmann (14 out of 22 patents)

4. Lutz Barnscheid (13 out of 18 patents)

5. Achim Kless (12 out of 30 patents)

6. Stefan Schunk (12 out of 36 patents)

7. Paul Ratcliffe (11 out of 15 patents)

8. Ingo Konetzki (10 out of 16 patents)

9. Wolfgang Schröder (10 out of 25 patents)

10. Sebastian Schwier (9 out of 12 patents)

11. Tobias Craan (9 out of 14 patents)

12. Gregor Bahrenberg (8 out of 46 patents)

13. Simon Lucas (8 out of 12 patents)

14. Werner Guenter Englberger (8 out of 58 patents)

15. Klaus Wening (7 out of 7 patents)

Core Competencies:

Substituted Pyrrolidine Amides

Abuse-Proofed Dosage Form

Tamper-Resistant Tablet

Pain Treatment Formulations

TRPV1 Agonists

Oxidation-Stabilized Dosage Form

Crystallization Method

Pyrazole Amides

Heteroaryl Substituted Sulfones

Stable Formulation

Pharmaceutical Combination

Immediate Drug Release

107 patents: Sort by Forward Citations

1. 12358907 - Substituted pyrrolidine amides III (2025-07-15),

2. 12110293 - Substituted triazolo quinoxaline derivatives (2024-10-08),

3. 11999699 - Substituted pyrazole amides (2024-06-04),

4. 11981677 - Further substituted triazolo quinoxaline derivatives (2024-05-14),

5. 11844865 - Abuse-proofed oral dosage form (2023-12-19),

6. 11739049 - Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol (2023-08-29),

7. 11344512 - Titration of tapentadol (2022-05-31),

8. 11224576 - Process for the production of an abuse-proofed dosage form (2022-01-18),

9. 11013701 - Stable formulation for parenteral administration of tapentadol (2021-05-25),

10. 10981918 - Further substituted triazolo quinoxaline derivatives (2021-04-20),

11. 10912763 - Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine (2021-02-09),

12. 10864164 - Tamper-resistant tablet providing immediate drug release (2020-12-15),

13. 10842750 - Protecting oral overdose with abuse deterrent immediate release formulations (2020-11-24),

14. 10813891 - Method of inhibiting chronification of pain (2020-10-27),

15. 10813890 - Pharmaceutical combination (2020-10-27),

GRUNENTHAL GMBH is a pharmaceutical company based in Germany. They specialize in the research, development, and marketing of innovative therapies for patients with severe and debilitating diseases. With a focus on pain management and therapeutics, GRUNENTHAL GMBH strives to improve the quality of life for patients globally. For more information, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

107 Patents

#4 in Aachen

#587 in Germany

#7,110 in the World

Aachen, Germany

Grunenthal Gmbh

Forward Citations = 983

187 inventors:

Johannes Bartholomäus (18 out of 28 patents)

Florian Jakob (15 out of 24 patents)

Heinrich Kugelmann (14 out of 22 patents)

4. Lutz Barnscheid (13 out of 18 patents)

5. Achim Kless (12 out of 30 patents)

Please report any incorrect information to support@idiyas.com

Loading…